ReviewInternational journal of molecular sciences2023
Current and Novel Therapies for Eosinophilic Gastrointestinal Diseases.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 30 citations in OpenAlex.
- Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial.The lancet. Gastroenterology & hepatology · 2026Trial
- Real-World Infectious Outcomes with Dupilumab Compared with Proton Pump Inhibitors and Topical Steroids in Eosinophilic Esophagitis: A Multi-cohort Propensity Matched Analysis.Digestive diseases and sciences · 2026Article
- Prevalence and features of eosinophilic gastrointestinal disorders using the large real-world TriNetX database.The journal of allergy and clinical immunology. Global · 2026Article
- Clinical Patterns and Outcomes of Eosinophilic Esophagitis in Children and Adolescents at a Tertiary Care Center in Lebanon.Children (Basel, Switzerland) · 2026Article
- Eosinophilic Colitis in an Adult Ethiopian Patient.Case reports in gastrointestinal medicine · 2026Article
- Restoring balance in atopic disorders: insights into type 2 immunity and chronic inflammation.Frontiers in immunology · 2026Review
- Dupilumab as a rescue therapy for steroid-dependent eosinophilic gastritis in a child unresponsive to elimination diet: a case report.Frontiers in pediatrics · 2026Article
- Omalizumab-Induced Remission and Steroid Withdrawal in Refractory Eosinophilic Gastroenteritis with Severe Hypereosinophilia: A Case Report.Clinical and experimental gastroenterology · 2026Article
- The Overlooked Burden of Atopic Comorbidities in Eosinophilic Esophagitis: Insights from a Real-Life Comprehensive Multidisciplinary Evaluation.Journal of clinical medicine · 2025Article
- A Unified Pathogenesis of Allergic Diseases; The Protein-Homeostasis-System Hypothesis.International journal of molecular sciences · 2025Review
- Chronic Eosinophilic Gastritis Presenting as Gastric Outlet Obstruction in a Young Man: A Case Report.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Translational approaches to the study of eosinophils in vasculitis.Rheumatology (Oxford, England) · 2025Review
- Practical concepts and strategies for early diagnosis and management of eosinophilic gastrointestinal disorders in East-Asian children.Clinical and experimental pediatrics · 2025Article
- Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives.Journal of clinical medicine · 2025Review
- CART-induced eosinophilic colitis with good response to corticosteroids and infliximab: a case report.Therapeutic advances in medical oncology · 2025Article
- Age-Dependent Clinical Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis.Journal of asthma and allergy · 2025Article
- Combined eosinophilic gastroenteritis and ulcerative colitis successfully treated by vedolizumab: a case report.Intestinal research · 2025Article
- The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases.Cells · 2024Review
- A Case Report of Post-COVID-19 Eosinophilic Enteritis: An Uncommon Diagnosis in an Adult.Cureus · 2024Article
- Bridging the divide: unveiling mutual immunological pathways of cancer and pregnancy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic gastrointestinal diseases (EGIDs) are an emerging group of pathological entities characterized by an eosinophil-predominant infiltration of different tracts of the gut in the absence of secondary causes of eosinophilia. According to the specific tract of the gut involved, EGIDs can be classified into eosinophilic esophagitis (EoE), eosinophilic gastritis (EoG), eosinophilic enteritis (EoN), and eosinophilic colitis (EoC). The epidemiology of EGIDs is evolving rapidly. EoE, once considered a rare disease, now has an incidence and prevalence of 7.7 new cases per 100,000 inhabitants per years and 34.4 cases per 100,000 inhabitants per year, respectively. Fewer data are available regarding non-EoE EGIDs, whose prevalence are estimated to range between 2.1 and 17.6 in 100,000 individuals, depending on age, sex, and ethnicity. Diagnosis requires the presence of suggestive symptoms, endoscopic biopsies showing abnormal values of eosinophils infiltrating the gut, and exclusion of secondary causes of eosinophilia. EoE typically presents with dysphagia and episodes of food bolus impactions, while EoG, EoN, and EoC may all present with abdominal pain and diarrhea, with or without other non-specific symptoms. In addition, although different EGIDs are currently classified as different entities, there may be overlap between different diseases in the same patient. Despite EGIDs being relatively novel pathological entities, the research on possible treatments is rapidly growing. In this regard, several randomized controlled trials are currently ongoing to investigate novel molecules, including ad-hoc steroid formulations, immunosuppressants, and mostly monoclonal antibodies that target the specific molecular mediators of EGIDs. This narrative review provides an up-to-date overview of available and investigational drugs for different EGIDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.